

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

CHANGE OF EXECUTIVE DIRECTORS

The Board announces that, with effect from 28 September 2026:

1. Mr. Wu Heng Yao has been appointed as an executive Director; and
2. Mr. Su Xuejun has resigned as an executive Director due to his desire to focus on his other work arrangements.

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of SSY Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Wu Hengyao (“**Mr. Wu**”) has been appointed as an executive Director with effect from 28 September 2026.

The biographical details of Mr. Wu are set out as below:

Mr. Wu Heng Yao, aged 57, is currently a director of New Orient Investments Pharmaceutical Holding (Hong Kong) Limited and Shijiazhuang No. 4 Pharmaceutical Co., Ltd.* (石家莊四藥有限公司) (“**Shijiazhuang No. 4**”), both being wholly-owned subsidiaries of the Company, and the president of Shijiazhuang No. 4. Mr. Wu has a Master’s degree in Business Administration from Tianjin University of Finance and Economics, holds the qualification of a Senior Engineer* (高級工程師) in the People’s Republic of China, and was the organization section chief and youth league secretary* (組織科長及團委書記) at the Personnel and Education Department of Hebei Branch of the Agricultural Development Bank of China* (中國農業發展銀行河北省分行人事教育處). After joining Shijiazhuang No. 4 in year 2004, Mr. Wu held the positions of manager of the sales department of Shijiazhuang No. 4 and deputy general manager of Shijiazhuang No. 4, and has over 20 years of experience in pharmaceutical sales and business management.

Mr. Wu has entered into a service agreement with the Company in respect of his directorship and his existing positions with the Group for a term of three years, and his appointment as director is subject to retirement by rotation and re-election at the upcoming annual general meeting of the Company in accordance with the articles of association of the Company. Under his service agreement, Mr. Wu will not receive any directors' fee but Mr. Wu will be entitled to a basic salary of HK\$1,900,000 per annum and discretionary bonus, which is determined at the recommendation of the remuneration committee of the Company and with reference to his duties and responsibilities within the Group, his experience and qualifications and prevailing market conditions.

Save as disclosed above, Mr. Wu has confirmed that he (i) does not hold any other position with the Company or other members of the Group; (ii) has not held any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) does not hold any other major appointments and professional qualifications.

As at the date of this announcement, Mr. Wu has confirmed that he does not have (i) any interests in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) any relationship with any Director, senior management or substantial or controlling shareholders of the Company.

Save as disclosed above, there is no information relating to Mr. Wu that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there is no other matter in relation to the appointment of Mr. Wu that needs to be brought to the attention of the shareholders of the Company.

The Company would like to take this opportunity to express its warmest welcome to Mr. Wu on joining the Board.

RESIGNATION OF EXECUTIVE DIRECTOR

The Board announces that Mr. Su Xuejun (“**Mr. Su**”) has resigned as an executive Director with effect from 28 September 2026 due to his desire to focus on his other work arrangements.

Mr. Su has confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company in relation to his resignation.

The Board would like to take this opportunity to express its sincere appreciation to Mr. Su for his valuable contributions to the Company during his tenure of office.

By Order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 28 September 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.

* *for identification purpose only*